Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Short Communication

TB infection and BCG vaccination: are we protected from COVID-19?

M. Madana, S. Pahuja, A. Mohana, R.M. Pandeya, K. Madana, V. Hadda, P. Tiwaria, R. Guleria, S. Mittala,*

*Department of Pulmonary, Critical Care and Sleep Medicine, All India Institute of Medical Sciences (AIIMS), New Delhi, India

Abstract

Objectives: The incidence of emerging coronavirus disease 2019 (COVID-19) disease is variable across the different parts of the world. Apart from travel patterns, other factors determining this difference may include host immune response. The aim of this study was to assess the effect of tuberculosis (TB) endemicity and Bacille Calmette-Guerin (BCG) coverage on COVID-19.

Study design: This was a cross-sectional study.

Methods: We reviewed available data regarding TB incidence, BCG coverage (as per the World Health Organization), and COVID-19 incidence of 174 countries. We divided the countries into four cohorts depending on annual TB incidence and BCG coverage.

Results: Countries with high TB incidence had lower COVID-19 than countries with low TB incidence. Similarly, countries with high BCG coverage had lower incidence of COVID-19, suggesting some protective mechanisms in TB-endemic areas. However, the ecological differences and different testing strategies between countries could not be accounted for in this analysis.

Conclusion: Higher TB incidence and BCG coverage were found to be associated with lesser incidence of COVID-19. This outcome paves the way for further research into pathogenesis and immune response in COVID-19.

© 2020 The Royal Society for Public Health. Published by Elsevier Ltd. All rights reserved.
Another issue is that the protection provided by BCG vaccine may vary among different populations. For example, a study showed that the protection provided by BCG vaccine in high-TB-burden countries is lower than that in low-TB-burden countries. The median CFR was 1.42 in group 1, 1.43 in group 2, and 0 in group 3 and group 4, without any significant difference between the groups. 

Our analysis demonstrated that high-TB-burden countries had a lower incidence of COVID-19, irrespective of the BCG vaccine status of the country. On the other hand, in low-TB-burden countries, BCG vaccine might confer protection against COVID-19. This probable relationship between TB and COVID-19 may be explained by cross-immunity between Mycobacterium species and COVID-19, which may be conferred by either latent or previous TB infection or BCG vaccination. Various vaccines including the BCG can produce positive non-specific immune effects leading to enhanced response against other non-mycobacterial pathogens such as the vaccinia virus. Another possible explanation is that COVID-19 and TB share common Th1 immune pathway, and it seems plausible that latent TB infection or a past TB infection could lead to a better immune response to SARS-CoV-2. As mentioned earlier, BCG vaccination for COVID-19 may have a protective role in low-TB-burden countries, thus supporting a role of BCG vaccination as prophylaxis to individuals at high risk of COVID-19 and its complications in these countries. A clinical trial with this intent is already underway (https://clinicaltrials.gov/ct2/show/NCT04327206). This analysis has several limitations as the countries are in different stages of the disease, and it may be premature to infer the effect of TB endemicity on COVID-19 incidence. Second, the administrative strategies to prevent transmission of infection also vary significantly between countries. Some countries have resorted to aggressive testing and abandoning all social get-togethers, while others have not. It might have affected the exact incidence of disease, thus affecting our study outcomes. The number of countries in group 3 was low; thus, finding the BCG effect in high-TB-burden countries is not possible. We were also not able to account for the ecological differences between the countries while analyzing these data sets. The countries vary in the form of the age structure of the population, economic status, social practices between various subpopulations, and hygiene practices. All these factors may contribute to the variable occurrence of COVID-19. The United Kingdom (UK) has reported a significant proportion of deaths due to COVID-19 in minority populations such as blacks and Asians, which are more likely to have received BCG vaccination or had a history of previous TB, but the data on their duration of stay in the UK have also not been analyzed so far. Another issue is that the protection provided by BCG vaccine may vary among different populations. For example, a study showed that the protection provided by BCG vaccine in high-TB-burden countries is lower than that in low-TB-burden countries. The median CFR was 1.42 in group 1, 1.43 in group 2, and 0 in group 3 and group 4, without any significant difference between the groups. 

Our analysis demonstrated that high-TB-burden countries had a lower incidence of COVID-19, irrespective of the BCG vaccine status of the country. On the other hand, in low-TB-burden countries, BCG vaccine might confer protection against COVID-19. This probable relationship between TB and COVID-19 may be explained by cross-immunity between Mycobacterium species and COVID-19, which may be conferred by either latent or previous TB infection or BCG vaccination. Various vaccines including the BCG can produce positive non-specific immune effects leading to enhanced response against other non-mycobacterial pathogens such as the vaccinia virus. Another possible explanation is that COVID-19 and TB share common Th1 immune pathway, and it seems plausible that latent TB infection or a past TB infection could lead to a better immune response to SARS-CoV-2. As mentioned earlier, BCG vaccination for COVID-19 may have a protective role in low-TB-burden countries, thus supporting a role of BCG vaccination as prophylaxis to individuals at high risk of COVID-19 and its complications in these countries. A clinical trial with this intent is already underway (https://clinicaltrials.gov/ct2/show/NCT04327206). This analysis has several limitations as the countries are in different stages of the disease, and it may be premature to infer the effect of TB endemicity on COVID-19 incidence. Second, the administrative strategies to prevent transmission of infection also vary significantly between countries. Some countries have resorted to aggressive testing and abandoning all social get-togethers, while others have not. It might have affected the exact incidence of disease, thus affecting our study outcomes. The number of countries in group 3 was low; thus, finding the BCG effect in high-TB-burden countries is not possible. We were also not able to account for the ecological differences between the countries while analyzing these data sets. The countries vary in the form of the age structure of the population, economic status, social practices between various subpopulations, and hygiene practices. All these factors may contribute to the variable occurrence of COVID-19. The United Kingdom (UK) has reported a significant proportion of deaths due to COVID-19 in minority populations such as blacks and Asians, which are more likely to have received BCG vaccination or had a history of previous TB, but the data on their duration of stay in the UK have also not been analyzed so far. Another issue is that the protection provided by BCG vaccine may also wane with age and thus predisposing the elderly population to a higher risk of disease. Finally, it is crucial to understand that these data only provide a correlation rather than a causal association, suggesting the need for prospective evaluation.

We conclude that there might be an association of low BCG coverage and low TB incidence with poor outcomes in COVID-19. Future research into the pathogenesis of COVID-19 may further improve our understanding of TB and COVID-19 relationship.

### Author statements

#### Ethical approval

Ethical approval was not deemed necessary as this was an analysis of publically available data. WHO data was used after obtaining prior permission.

#### Funding

None declared.

#### Competing interests

None declared.

#### Authors’ contribution

All the authors have contributed equally.

#### References

1. Jamil T, Alam IS, Gojobori T, Duarte C. No evidence for temperature-dependence of the COVID-19 epidemic. medRxiv 2020 Jan 1. 2020.03.29.20046706.
2. Miller A, Reandelar MJ, Fasiglione K, Roumenova V, Li Y, Otazu GH. Correlation between universal BCG vaccination policy and reduced morbidity and mortality for COVID-19: an epidemiological study. medRxiv 2020 Jan 1. 2020.03.24.20042937.
3. Who int. Coronavirus [online] Available at: https://www.who.int/emergencies/diseases/novel-coronavirus-2019, 2020. [Accessed 1 April 2020].
4. World Health Organization. Global tuberculosis report [online] Available at: https://www.who.int/tb/publications/global_report/en/, 2020. [Accessed 1 April 2020].
5. Worldometers info. Coronavirus update (live): 607,166 cases and 27,674 deaths from COVID-19 virus outbreak - worldometer [online] Available at: https://www.worldometers.info/coronavirus/, 2020. [Accessed 1 April 2020].
6. Ljub doma IV, Pantaleev AV, Th1 and Th17 cells in tuberculosis: protection, pathology, and biomarkers. Mediat Inflamm 2015;2015:1–13.
7. Prompetchara E, Ketloy C, Palaga T. Immune responses in COVID-19 and potential vaccines: lessons learned from SARS and MERS epidemic. Asian Pac J Allergy Immunol 2020 Mar;38(1):1–9.